Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 879.99 Billion KRW | 1.65% |
| 2022 | 865.67 Billion KRW | -3.0% |
| 2021 | 892.42 Billion KRW | 0.57% |
| 2020 | 887.39 Billion KRW | 4.83% |
| 2019 | 846.47 Billion KRW | -8.0% |
| 2018 | 920.08 Billion KRW | 365.66% |
| 2017 | 197.58 Billion KRW | -59.84% |
| 2016 | 491.98 Billion KRW | 10.52% |
| 2015 | 445.16 Billion KRW | 8.69% |
| 2014 | 409.56 Billion KRW | 3.4% |
| 2013 | 396.09 Billion KRW | 1.36% |
| 2012 | 390.76 Billion KRW | 1.73% |
| 2011 | 384.13 Billion KRW | 11.36% |
| 2010 | 344.94 Billion KRW | 18.93% |
| 2009 | 290.04 Billion KRW | 8.51% |
| 2008 | 267.31 Billion KRW | 5.05% |
| 2007 | 254.45 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 881.15 Billion KRW | 0.06% |
| 2024 Q1 | 880.6 Billion KRW | 0.07% |
| 2023 Q2 | 901.93 Billion KRW | 1.24% |
| 2023 Q1 | 890.86 Billion KRW | 2.91% |
| 2023 FY | 879.99 Billion KRW | 1.65% |
| 2023 Q4 | 879.99 Billion KRW | -4.28% |
| 2023 Q3 | 919.35 Billion KRW | 1.93% |
| 2022 Q2 | 906.12 Billion KRW | 0.8% |
| 2022 Q1 | 898.92 Billion KRW | 0.73% |
| 2022 FY | 865.67 Billion KRW | -3.0% |
| 2022 Q4 | 865.67 Billion KRW | -5.53% |
| 2022 Q3 | 916.33 Billion KRW | 1.13% |
| 2021 Q3 | 908.09 Billion KRW | 0.99% |
| 2021 Q4 | 892.42 Billion KRW | -1.73% |
| 2021 FY | 892.42 Billion KRW | 0.57% |
| 2021 Q1 | 893.14 Billion KRW | 0.65% |
| 2021 Q2 | 899.18 Billion KRW | 0.68% |
| 2020 Q4 | 887.39 Billion KRW | 1.03% |
| 2020 Q2 | 870.39 Billion KRW | 3.03% |
| 2020 Q3 | 878.36 Billion KRW | 0.92% |
| 2020 FY | 887.39 Billion KRW | 4.83% |
| 2020 Q1 | 844.76 Billion KRW | -0.2% |
| 2019 Q2 | 909.04 Billion KRW | 0.47% |
| 2019 Q4 | 846.47 Billion KRW | -5.59% |
| 2019 Q1 | 904.78 Billion KRW | -1.66% |
| 2019 Q3 | 896.63 Billion KRW | -1.37% |
| 2019 FY | 846.47 Billion KRW | -8.0% |
| 2018 Q2 | 299.21 Billion KRW | 47.58% |
| 2018 Q3 | 345.74 Billion KRW | 15.55% |
| 2018 FY | 920.08 Billion KRW | 365.66% |
| 2018 Q1 | 202.73 Billion KRW | 2.61% |
| 2018 Q4 | 920.08 Billion KRW | 166.12% |
| 2017 Q1 | 485.73 Billion KRW | -1.27% |
| 2017 Q2 | 199.61 Billion KRW | -58.9% |
| 2017 FY | 197.58 Billion KRW | -59.84% |
| 2017 Q3 | 202.62 Billion KRW | 1.51% |
| 2017 Q4 | 197.58 Billion KRW | -2.49% |
| 2016 FY | 491.98 Billion KRW | 10.52% |
| 2016 Q4 | 491.98 Billion KRW | 0.0% |
| 2015 Q2 | 433.54 Billion KRW | -1.05% |
| 2015 FY | 445.16 Billion KRW | 8.69% |
| 2015 Q3 | 433.74 Billion KRW | 0.05% |
| 2015 Q1 | 438.13 Billion KRW | 6.97% |
| 2014 Q1 | 398.74 Billion KRW | 0.67% |
| 2014 Q2 | 411.16 Billion KRW | 3.12% |
| 2014 Q3 | 422.48 Billion KRW | 2.75% |
| 2014 Q4 | 409.56 Billion KRW | -3.06% |
| 2014 FY | 409.56 Billion KRW | 3.4% |
| 2013 Q3 | 402.99 Billion KRW | 0.38% |
| 2013 Q4 | 396.09 Billion KRW | -1.71% |
| 2013 Q2 | 401.47 Billion KRW | 4.03% |
| 2013 Q1 | 385.9 Billion KRW | -1.24% |
| 2013 FY | 396.09 Billion KRW | 1.36% |
| 2012 Q3 | 402.91 Billion KRW | 0.61% |
| 2012 Q2 | 400.48 Billion KRW | 2.0% |
| 2012 Q1 | 392.61 Billion KRW | 2.21% |
| 2012 FY | 390.76 Billion KRW | 1.73% |
| 2012 Q4 | 390.76 Billion KRW | -3.01% |
| 2011 FY | 384.13 Billion KRW | 11.36% |
| 2011 Q4 | 384.13 Billion KRW | 1.11% |
| 2011 Q3 | 379.89 Billion KRW | 3.23% |
| 2011 Q2 | 367.99 Billion KRW | -1.63% |
| 2011 Q1 | 374.1 Billion KRW | 8.45% |
| 2010 Q1 | 328.06 Billion KRW | 13.11% |
| 2010 Q2 | 337.45 Billion KRW | 2.86% |
| 2010 FY | 344.94 Billion KRW | 18.93% |
| 2010 Q4 | 344.94 Billion KRW | 2.05% |
| 2010 Q3 | 338.02 Billion KRW | 0.17% |
| 2009 Q3 | 289.08 Billion KRW | 1.84% |
| 2009 Q2 | 283.86 Billion KRW | 5.98% |
| 2009 Q1 | 267.85 Billion KRW | 0.2% |
| 2009 FY | 290.04 Billion KRW | 8.51% |
| 2009 Q4 | 290.04 Billion KRW | 0.33% |
| 2008 Q1 | 256.87 Billion KRW | 0.95% |
| 2008 Q2 | 262.23 Billion KRW | 2.09% |
| 2008 Q4 | 267.31 Billion KRW | 2.4% |
| 2008 Q3 | 261.04 Billion KRW | -0.45% |
| 2008 FY | 267.31 Billion KRW | 5.05% |
| 2007 Q3 | 251.94 Billion KRW | 1.66% |
| 2007 FY | 254.45 Billion KRW | 0.0% |
| 2007 Q2 | 247.82 Billion KRW | 3.73% |
| 2007 Q4 | 254.45 Billion KRW | 1.0% |
| 2007 Q1 | 238.91 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -343.964% |
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 55.036% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | -0.342% |
| HANDOK Inc. | 790.33 Billion KRW | -11.344% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -415.764% |
| Yuhan Corporation | 2814.07 Billion KRW | 68.729% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 33.091% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -841.384% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 54.919% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | -267.052% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -87.671% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -665.393% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | -272.015% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | -152.592% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -343.964% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | -109.928% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | -76.078% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | -49.305% |
| JW Holdings Corporation | 1176.26 Billion KRW | 25.187% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | -43.964% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 37.252% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -36.425% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -151.368% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -471.274% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | -137.401% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | -80.577% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | -343.964% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 18.373% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 50.291% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -36.425% |
| Yuhan Corporation | 2814.07 Billion KRW | 68.729% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | -288.347% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 11.446% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | -36.425% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | -109.572% |
| Korea United Pharm Inc. | 468.86 Billion KRW | -87.688% |
| CKD Bio Corp. | 293.78 Billion KRW | -199.538% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | -73.228% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | -55.759% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | -119.327% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | -151.368% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 39.561% |
| Boryung Corporation | 922.36 Billion KRW | 4.593% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | -98.886% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | -87.671% |
| JW Lifescience Corporation | 255.83 Billion KRW | -243.969% |